European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

MINIMAL SAPONIN-BASED ADJUVANT VACCINE PLATFORM

Objectif

ADJU-PLATFORM seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the efficient production of optimised saponin adjuvants and improved cost-effective vaccines. We have recently developed in the laboratory a potent, safe, stable and streamlined platform based on an optimised version of the vaccine adjuvant QS-21 that has led to patent applications and raised the interest of the pharmaceutical industry. In this PoC project, we aim to exploit our synthetic saponin technology to produce scalable adjuvant and vaccine candidates that outperform existing products more cost-effectively, lowering the risk profile of the commercialisation potential, while also achieving valorisation outcomes for market entry. The goal is to demonstrate our innovative minimal adjuvant platform in relevant settings for the advancement of novel adjuvant prototypes and molecular vaccines closer to the market.

The breakthrough innovation potential of ADJU-PLATFORM lies in the exploitation of this adjuvant vaccine platform for its application with additional formulation systems in a range of disease areas, expanding and improving the available vaccine solutions. The high purity and excellent chemical control over our synthetic platform compared to the heterogeneous natural product adjuvants, as well as its streamlined, modular nature and low-cost profile are distinctive attributes of our technology that will be valorised herein, making it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines. The main objectives are (1) demonstrate our synthetic technology platform for the streamlined and efficient development of scalable adjuvant and vaccine solutions and (2) implement valorisation opportunities of our platform and products by establishing an optimal IPR strategy and a “go-to-market” roadmap for the commercialisation.

Mots‑clés

Institution d’accueil

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
Contribution nette de l'UE
€ 150 000,00
Adresse
PARQUE TECNOLOGICO EDIFICIO 801 A
48160 DERIO VIZCAYA
Espagne

Voir sur la carte

Région
Noreste País Vasco Bizkaia
Type d’activité
Research Organisations
Liens
Coût total
Aucune donnée

Bénéficiaires (1)